← All trials
NCT05613842
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Jun 30, 2024
- First posted
- Nov 14, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- University of New South WalesReponsible party - principal investigator
- GMP BIO Co., LTD.Overall official - principal investigator
- Clarity Pharmaceuticals LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.